Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.37 and traded as low as $4.20. Galmed Pharmaceuticals shares last traded at $4.54, with a volume of 121,399 shares.
Wall Street Analyst Weigh In
Separately, StockNews.com began coverage on Galmed Pharmaceuticals in a research report on Wednesday, October 9th. They set a “sell” rating for the company.
Read Our Latest Analysis on Galmed Pharmaceuticals
Galmed Pharmaceuticals Stock Down 2.5 %
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last released its quarterly earnings data on Wednesday, August 28th. The biopharmaceutical company reported $2.16 earnings per share for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Further Reading
- Five stocks we like better than Galmed Pharmaceuticals
- What Investors Need to Know About Upcoming IPOs
- Texas Roadhouse Stock Steering for New Highs This Year
- How to Find Undervalued Stocks
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is a Dividend King?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.